CAR T cells targeting the glycoprotein GD2 show potent antitumor efficacy in high-risk ependymoma models
Publication date
2026-01-16
Authors
Tallon-Cobos, Antonio Carlos
Vazaios, Konstantinos
Waranecki, Piotr
van Hoesel, Marliek
Cornel, Annelisa M.
Schwalm, Benjamin
Mack, Norman
de Boed, Ella
van der Lugt, Jasper
Nierkens, Stefan
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by
Abstract
Aggressive pediatric brain tumor models of ependymoma are highly sensitive to GD2-directed (CAR T) cell therapy.
Keywords
Brain cancer, Cancer immunotherapy, Immunology, Neuroscience, Oncology, General Medicine
Citation
Tallon-Cobos, A C, Vazaios, K, Waranecki, P, van Hoesel, M, Cornel, A, Schwalm, B, Mack, N, de Boed, E, van der Lugt, J, Nierkens, S, Kool, M, Hoving, E W, Metselaar, D S & Hulleman, E 2026, 'CAR T cells targeting the glycoprotein GD2 show potent antitumor efficacy in high-risk ependymoma models', The Journal of clinical investigation, vol. 136, no. 2. https://doi.org/10.1172/JCI193332